Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.52 |
| ▸ | BTK | Q06187 | 3/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245604 | 0.86 | SYK (0.53) | CDK1AURKAEGFRSYKGSK3A | |
| SCHEMBL656260 | 0.80 | SYK (0.63) | AURKASYK | |
| SCHEMBL3839986 | 0.78 | SYK (0.57) | CDK1AURKAEGFRSYKGSK3A | |
| SCHEMBL655405 | 0.77 | MMP13 (0.57) | SYK | |
| SCHEMBL13911531 | 0.74 | SYK (0.41) | CDK1AURKAEGFRSYK | |
| SCHEMBL13153576 | 0.74 | SYK (0.41) | CDK1AURKAEGFRSYK | |
| SCHEMBL656550 | 0.73 | SYK (0.57) | CDK1AURKAEGFRBTKSYK | |
| SCHEMBL656169 | 0.71 | SYK (0.64) | AURKASYK | |
| SCHEMBL16236301 | 0.71 | HRH4 (0.57) | — | |
| SCHEMBL11987615 | 0.70 | PTK2 (0.61) | PTK2GSK3AGSK3BPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188276-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188276-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090171086-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090171086-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171086-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | CDK1 1205/4885PTK2 312/4885CDK4 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.